Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62012TA0502

Case T-502/12: Judgment of the General Court of 9 April 2014  — Ferring v OHIM — Tillotts Pharma (OCTASA) (Community trade mark — Opposition proceedings — Application for Community word mark OCTASA — Earlier national, Benelux and international word marks PENTASA and OCTOSTIM — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009)

OJ C 175, 10.6.2014, p. 40–40 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

10.6.2014   

EN

Official Journal of the European Union

C 175/40


Judgment of the General Court of 9 April 2014 — Ferring v OHIM — Tillotts Pharma (OCTASA)

(Case T-502/12) (1)

((Community trade mark - Opposition proceedings - Application for Community word mark OCTASA - Earlier national, Benelux and international word marks PENTASA and OCTOSTIM - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009))

2014/C 175/53

Language of the case: English

Parties

Applicant: Ferring BV (Haarlem, Netherlands) (represented initially by I. Fowler, Solicitor, A. Renck and J. Fuhrmann, lawyers, and subsequently by I. Fowler, A. Renck and D. Slopek, lawyer)

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: P. Bullock, Agent)

Other party to the proceedings before the Board of Appeal of OHIM, intervener before the General Court: Tillotts Pharma AG (Ziefen, Switzerland) (represented by: T. Alkin, Barrister)

Re:

Action against the decision of the Fourth Board of Appeal of OHIM of 6 September 2012 (Case R 1216/2011-4), concerning opposition proceedings between Ferring BV and Tillotts Pharma AG.

Operative part of the judgment

The Court:

1.

Annuls the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM) of 6 September 2012 (Case R 1216/2011-4);

2.

Orders OHIM to bear its own costs and to pay half of the costs incurred by Ferring BV;

3.

Orders Tillotts Pharma AG to bear its own costs and to pay half of the costs incurred by Ferring.


(1)  OJ C 26, 26. 1. 2013.


Top